Answers are grounded in this paper and cite their sources.
Elevated circulating IGFBP-2 levels were associated with an increased risk of both all-cause dementia and Alzheimer's disease. Addition of IGFBP2 plasma levels to a model of traditional risk factors significantly improved dementia risk classification. Manipulation of insulin-like growth factor signaling via IGFBP-2 may be a promising therapeutic target for dementia.
No takes yet. Share an insight, caveat, or question.
McGrath et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: